ReviewFrontiers in endocrinology2025
Role of lactoferrin and its derived peptides in metabolic syndrome treatment.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Lactoferrin in Obese Children and Adolescents with Metabolic Dysfunction-Associated Steatotic Disease: A Randomized Controlled Study.Paediatric drugs · 2026Trial
- Lactoferrin as a multi-target nutritional modulator in type-2 diabetes.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of metabolic syndrome is increasing globally year by year, which has prompted researchers to actively seek and develop natural biotherapeutics to address this challenge. Lactoferrin (LF), as a multifunctional iron-binding natural transferrin, has garnered significant attention due to its potential role in regulating metabolism and the immune system. Recent studies show lactoferrin may influence lipid metabolism and glucose-insulin balance, and its levels are linked to body measurements. We systematically summarized the phenotypic and genotypic changes of LF in patients with metabolic syndrome, and the effect of exogenous LF on the treatment of metabolic syndrome. We also recapitulate LF can alleviate insulin resistance by inhibiting the NF-κB inflammatory pathway, activating the IRS/PI3K/Akt/Glut signaling pathway, and inhibiting the renin-angiotensin system to reduce the blood pressure, therefore improving the metabolic syndrome. This provides an important theoretical basis for the clinical application of LF in metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.